Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of porfimer sodium.
The sonodynamically induced antitumor effect of porfimer sodium (PF) was evaluated on a chemically induced mammary tumor in Sprague-Dawley rats. The timing of 24 h after the administration of PF was chosen for the ultrasonic exposure, based on pharmacokinetic analysis of the PF concentrations in the tumor, plasma, skin and muscle. At a PF dose not less than 2.5 mg/kg and at a free-field ultrasonic intensity not less than 3 W/cm2, the synergistic effect between PF administration and ultrasonic exposure on the tumor growth inhibition was significant. The ultrasonic intensity showed a relatively sharp threshold for the synergistic antitumor effect, which is typical of an ultrasonic effect mediated by acoustic cavitation. These results suggest that PF is a potentially useful as a sonosensitizer for sonodynamic treatment of chemically induced tumors.
School of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
Nagahiko
N
Yumita
Nobuo
N
Okuyama
Kazuaki
K
Sasaki
Shin-ichiro
S
Umemura
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002273:Carcinogens / Q000633:toxicity; D003131:Combined Modality Therapy; D017323:Dihematoporphyrin Ether / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000139:chemically induced* / Q000628:therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D014464:Ultrasonic Therapy
D000970:Antineoplastic Agents; D002273:Carcinogens; D015127:9,10-Dimethyl-1,2-benzanthracene; D017323:Dihematoporphyrin Ether